ClinicalTrials.gg
CompletedNCT01999218Updated Apr 2, 2019Results posted

Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

A Phase 3 interventional study of Ertugliflozin 5 mg and Ertugliflozin 10 mg in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,326
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.

Enrollment
2nd of 28
1,326 · median 83
Started
2013
with 5 others
Phase 3
11 of 28
none open now
Registered
11th of 28
by date
Lead sponsor
18 of 28
Merck Sharp & Dohme LLC

Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 2nd largest by enrollment, is one of 6 that started in 2013, is one of 11 in phase 3, and was the 11th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ertugliflozin

ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of the addition of ertugliflozin (MK-8835/PF-04971729) compared with the addition of glimepiride in participants with T2DM who have inadequate glycemic control on metformin. The primary hypothesis of this study is that after 52 weeks, the change from baseline in hemoglobin A1c (A1C) in participants treated with the addition of ertugliflozin 15 mg once daily is non-inferior compared with that in participants treated with the addition of glimepiride.

Read the detailed description

The duration of the trial will be up to approximately 122 weeks. This will include a 1-week screening period, an up to 13-week wash-off/titration/dose stabilization period, a 2-week placebo run-in period, a 104-week double-blind, active comparator-controlled treatment period, and a post-treatment telephone contact 14 days after the last dose of study drug.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of T2DM in accordance to American Diabetes Association guidelines
  • On metformin monotherapy or metformin in combination with a single allowable anti-hyperglycemic agent (AHA), DPP-4 inhibitors, meglitinides and AGIs are listed as allowable AHAs along with sulfonylureas prior to study participation.
  • (BMI) ≥18.0 kg/m\^2
  • Male or female not of
  • If a female of reproductive potential, agree to remain abstinent or to use (or have their partner use) 2 acceptable combinations of while participating in the trial and for 14 days after the last use of study drug.

Exclusion criteria

Exclusion Criteria:

  • History or presence of type 1 diabetes mellitus or a history of ketoacidosis
  • History of other specific types of diabetes (eg, genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and post-organ transplant).
  • A known or intolerance to any sodium-glucose co-transporter 2 (SGLT2) inhibitor
  • Use of the following prohibited therapeutic agents within 12 weeks of study participation: insulin, injectable anti-hyperglycemic agents, pioglitazone or rosiglitazone, another SGLT2 inhibitor, bromocriptine (Cycloset®), colesevelam (Welchol®), and any other non-approved anti-hyperglycemic therapy
  • Known hypersensitivity or intolerance to metformin or glimepiride
  • On a weight-loss program or medication or medication associated with weight changes and is not weight-stable (>=5% change in body weight in the last 6 months)
  • History of bariatric surgery less than 12 months prior to study participation
  • History of myocardial infarction, unstable angina, arterial revascularization, stroke, , or (NYHA) functional class III-IV heart failure within 3 months of study participation
  • Active, obstructive uropathy or an indwelling urinary catheter
  • A history of ≤5 years prior to study participation, except for adequately treated basal or squamous cell skin cancer or in situ cervical cancer
  • Known history of (HIV)
  • Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells
  • A medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active or C (assessed by medical history), primary biliary cirrhosis, or symptomatic gallbladder disease
  • Any malabsorption condition
  • Being treated for hyperthyroidism, or on thyroid replacement therapy that has not been at a stable dose for at least 6 weeks prior to study participation
  • Previous randomization in a study with ertugliflozin
  • Participation in other studies involving drug(s) within 30 days of study participation and/or during the pre-randomization period
  • A surgical procedure within 6 weeks prior to study participation or planned major surgery during the trial
  • A positive urine pregnancy test
  • Pregnant or breast-feeding, or expecting to conceive during the trial, including 14 days following the last dose of study drug
  • Undergoing hormonal therapy in preparation to donate eggs during the period of the trial, including 14 days following the last dose of study drug
  • Consumption of more than 2 alcoholic drinks per day or engages in binge drinking
  • Donation of blood or blood products within 6 weeks of study participation or plans to donate blood or blood products at any time during the trial
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,326 participants (actual)

Study arms

  • Experimental
    Ertugliflozin 5 mg

    Ertugliflozin 5 mg once daily (QD) from Day 1 to Week 104

    Drug: Ertugliflozin 5 mg · Drug: Placebo to Ertugliflozin · Drug: Placebo to Glimepiride · Drug: Metformin · Drug: Sitagliptin

  • Experimental
    Ertugliflozin 15 mg

    Ertugliflozin 15 mg QD from Day 1 to Week 104

    Drug: Ertugliflozin 5 mg · Drug: Ertugliflozin 10 mg · Drug: Placebo to Glimepiride · Drug: Metformin · Drug: Sitagliptin

  • Active comparator
    Glimepiride up to 8 mg

    Glimepiride to a maximum of 8 mg QD from Day 1 to Week 104

    Drug: Glimerpiride · Drug: Placebo to Ertugliflozin · Drug: Metformin · Drug: Sitagliptin

Interventions

  • Ertugliflozin, 5 mg, oral, once daily, from Day 1 to Week 104

    Also known as: MK-8835

  • Ertugliflozin, 10 mg, oral, once daily from Day 1 to Week 104.

    Also known as: MK-8355

  • DrugGlimerpiride

    Glimepiride, oral tablets, initiated at 1 mg daily and titrated up to the maximum approved dose (8 mg daily based on the local country label) or maximum tolerated dose

  • DrugPlacebo to Ertugliflozin

    Matching placebo to ertugliflozin, 5 mg and/or 10 mg, oral, once daily, from Day 1 to Week 104

  • DrugPlacebo to Glimepiride

    Matching placebo to glimepiride, 1 mg or 2 mg, oral, once daily, from Day 1 to Week 104.

  • Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.

  • Open label, oral, once daily, rescue medication as required.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1C (A1C) at Week 52: Excluding Rescue Approach

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 52 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication. The primary study objective was the MK-8835 15 mg vs. glimepiride comparison; the MK-8835 5mg vs glimerpiride comparison was a secondary study objective.

    Time frame: Baseline and Week 52

  2. Percentage of Participants Experiencing An Adverse Event (AE) Up to Week 106

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to Week 106

  3. Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 104

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to Week 104

Secondary outcomes

  1. Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 52: Excluding Rescue Approach

    Symptomatic hypoglycemia was an event with clinical symptoms reported by the investigator as hypoglycemia (biochemical documentation not required). Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.

    Time frame: Up to Week 52

  2. Change From Baseline in Body Weight at Week 52 Excluding Rescue Approach

    This change from baseline reflects the Week 52 body weight minus the Week 0 body weight. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.

    Time frame: Baseline and Week 52

  3. Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 Excluding Rescue Approach

    This change from baseline reflects the Week 52 SBP minus the Week 0 SBP. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.

    Time frame: Baseline and Week 52

07

Results

Posted May 11, 2018

Participant flow

The trial was conducted in 16 countries at 232 trial centers in Argentina, Canada, Czech Republic, Hungary, South Korea, Lithuania, Mexico, Philippines, Poland, Romania, Russia, Slovakia, South Africa, Taiwan, Ukraine, and the United States.

Participant flow — Overall Study
MilestoneErtugliflozin 5 mgErtugliflozin 15 mgGlimepiride
Started448441437
Treated448440437
Site issue445435435
Completed339340327
Not completed109101110
Withdrew: Hyperglycemia181717
Withdrew: Lack of efficacy101
Withdrew: Lost to follow-up221718
Withdrew: Non-compliance with study drug641
Withdrew: Physician decision146
Withdrew: Protocol violation454
Withdrew: Screen failure010
Withdrew: Study terminated by sponsor7512
Withdrew: Participant moves253
Withdrew: Withdrawal by subject282934
Withdrew: Creatinine/egfr001
Withdrew: Death712
Withdrew: Excluded medication112
Withdrew: Adverse event977
Withdrew: Treated but excluded at 1 trial site352

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1C (A1C) at Week 52: Excluding Rescue Approach

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 52 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication. The primary study objective was the MK-8835 15 mg vs. glimepiride comparison; the MK-8835 5mg vs glimerpiride comparison was a secondary study objective.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · Percent
Change From Baseline in Hemoglobin A1C (A1C) at Week 52: Excluding Rescue Approach
PercentErtugliflozin 5 mgErtugliflozin 15 mgGlimepiride
Change From Baseline in Hemoglobin A1C (A1C) at Week 52: Excluding Rescue Approach-0.56 (-0.65 to -0.47)-0.64 (-0.73 to -0.55)-0.74 (-0.83 to -0.65)
Statistical analysis
  • Ertugliflozin 15 mg vs Glimepiride · Difference in the least squares means: 0.10 · 95% CI -0.02 to 0.22Constrained Longitudinal Data Analysis (cLDA) model with fixed effects for treatment, time, prior antihyperglycemic medication (monotherapy or dual therapy), baseline eGFR (continuous) and the interaction of time by treatment.
  • Ertugliflozin 5 mg vs Glimepiride · Difference in the least squares means: 0.18 · 95% CI 0.06 to 0.30Based on cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (monotherapy or dual therapy), baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.
PrimaryPercentage of Participants Experiencing An Adverse Event (AE) Up to Week 106

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to Week 106
Reported as:
Number · Percentage of Participants
Percentage of Participants Experiencing An Adverse Event (AE) Up to Week 106
Percentage of ParticipantsErtugliflozin 5 mgErtugliflozin 15 mgGlimepiride
Percentage of Participants Experiencing An Adverse Event (AE) Up to Week 10670.171.369.7
Statistical analysis
  • Ertugliflozin 15 mg vs Glimepiride · Difference in % vs. glimepiride: 1.6 · 95% CI -4.5 to 7.7
  • Ertugliflozin 5 mg vs Glimepiride · Difference in % vs. glimepiride: 0.5 · 95% CI -5.6 to 6.5
PrimaryPercentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 104

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to Week 104
Reported as:
Number · Percentage of Participants
Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 104
Percentage of ParticipantsErtugliflozin 5 mgErtugliflozin 15 mgGlimepiride
Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 1046.58.05.1
Statistical analysis
  • Ertugliflozin 15 mg vs Glimepiride · Difference in % vs. glimepiride: 3.0 · 95% CI -0.3 to 6.4
  • Ertugliflozin 5 mg vs Glimepiride · Difference in % vs. glimepiride: 1.5 · 95% CI -1.7 to 4.7
SecondaryPercentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 52: Excluding Rescue Approach

Symptomatic hypoglycemia was an event with clinical symptoms reported by the investigator as hypoglycemia (biochemical documentation not required). Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.

Time frame:
Up to Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 52: Excluding Rescue Approach
Percentage of ParticipantsErtugliflozin 5 mgErtugliflozin 15 mgGlimepiride
Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 52: Excluding Rescue Approach3.15.219.2
Statistical analysis
  • Ertugliflozin 15 mg vs Glimepiride · Based on Miettinen & Nurminen method · p = <0.001 · Difference in % vs. glimepiride: -14.0 · 95% CI -18.4 to -9.8
  • Ertugliflozin 5 mg vs Glimepiride · Based on Miettinen & Nurminen method · p = <0.001 · Difference in % vs. glimepiride: -16.1 · 95% CI -20.3 to -12.2
SecondaryChange From Baseline in Body Weight at Week 52 Excluding Rescue Approach

This change from baseline reflects the Week 52 body weight minus the Week 0 body weight. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · Kilograms
Change From Baseline in Body Weight at Week 52 Excluding Rescue Approach
KilogramsErtugliflozin 5 mgErtugliflozin 15 mgGlimepiride
Change From Baseline in Body Weight at Week 52 Excluding Rescue Approach-2.96 (-3.31 to -2.61)-3.38 (-3.73 to -3.03)0.91 (0.56 to 1.25)
Statistical analysis
  • Ertugliflozin 15 mg vs Glimepiride · Constrained Longitudinal Data analysis · p = <0.001 · Difference in lsm vs. glimepiride: -4.29 · 95% CI -4.77 to -3.80LSM=Least Squares Means
  • Ertugliflozin 5 mg vs Glimepiride · Constrained Longitudinal Data Analysis · p = <0.001 · Difference in the lsm vs. glimepiride: -3.87 · 95% CI -4.36 to -3.38
SecondaryChange From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 Excluding Rescue Approach

This change from baseline reflects the Week 52 SBP minus the Week 0 SBP. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 Excluding Rescue Approach
mmHgErtugliflozin 5 mgErtugliflozin 15 mgGlimepiride
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 Excluding Rescue Approach-2.25 (-3.36 to -1.13)-3.81 (-4.91 to -2.71)0.95 (-0.15 to 2.06)
Statistical analysis
  • Ertugliflozin 15 mg vs Glimepiride · Constrained Logitudinal Data Analysis · p = <0.001 · Difference in the lsm vs. glimepiride: -4.77 · 95% CI -6.29 to -3.25
  • Ertugliflozin 5 mg vs Glimepiride · Constrained Logitudinal Data Analysis · p = <0.001 · Difference in the lsm vs. glimepiride: -3.20 · 0.001% CI -4.73 to -1.67

Adverse events

Collected over Up to Week 106. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ertugliflozin 5 mg7/445 (1.6%)41/445 (9.2%)110/445 (24.7%)
Ertugliflozin 15 mg2/435 (0.5%)32/435 (7.4%)104/435 (23.9%)
Glimepiride1/435 (0.2%)30/435 (6.9%)165/435 (37.9%)
Most frequent serious events
Showing 10 of 123
Most frequent serious events
EventErtugliflozin 5 mgErtugliflozin 15 mgGlimepiride
Angina unstableCardiac disorders2/4450/4352/435
Chronic calculous cholecystitisHepatobiliary disorders0/4452/4350/435
Breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4452/4350/435
Coronary artery diseaseCardiac disorders2/4450/4350/435
Lobar pneumoniaInfections and infestations2/4450/4350/435
StrokeNervous system disorders2/4450/4350/435
Acute coronary syndromeCardiac disorders1/4451/4350/435
Acute myocardial infarctionCardiac disorders1/4451/4350/435
Cardiac failureCardiac disorders1/4451/4350/435
Myocardial infarctionCardiac disorders0/4451/4350/435
Most frequent other events
Most frequent other events
EventErtugliflozin 5 mgErtugliflozin 15 mgGlimepiride
HypoglycaemiaMetabolism and nutrition disorders14/44525/43582/435
Urinary tract infectionInfections and infestations27/44528/43529/435
Asymptomatic hypoglycaemiaMetabolism and nutrition disorders7/4454/43527/435
Upper respiratory tract infectionInfections and infestations27/44514/43518/435
HeadacheNervous system disorders25/44519/43519/435
Common coldInfections and infestations21/44517/43523/435
DiarrhoeaGastrointestinal disorders13/44512/43522/435

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(Years)Ertugliflozin 5 mgErtugliflozin 15 mgGlimepirideTotal
Mean58.8 ± 9.758.0 ± 9.957.8 ± 9.258.2 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)Ertugliflozin 5 mgErtugliflozin 15 mgGlimepirideTotal
Female221250213684
Male227191224642
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ertugliflozin 5 mgErtugliflozin 15 mgGlimepirideTotal
American Indian or Alaska Native53513
Asian818673240
Native Hawaiian or Other Pacific Islander0000
Black or African American17192561
White332316318966
More than one race13171646
Unknown or Not Reported0000
Body Weight
Body Weight(Kilograms)Ertugliflozin 5 mgErtugliflozin 15 mgGlimepirideTotal
Mean87.9 ± 18.985.6 ± 19.186.8 ± 20.786.8 ± 19.6
Hemoglobin A1C
Hemoglobin A1C(Percentage)Ertugliflozin 5 mgErtugliflozin 15 mgGlimepirideTotal
Mean7.81 ± 0.607.80 ± 0.607.76 ± 0.607.79 ± 0.60
Sitting Systolic Blood Pressure
Sitting Systolic Blood Pressure(Millimeters of mercury)Ertugliflozin 5 mgErtugliflozin 15 mgGlimepirideTotal
Mean130.2 ± 12.8130.8 ± 12.4129.9 ± 12.0130.3 ± 12.4
Prior Antihyperglycemic (AHA) Medication (Monotherapy or Dual Therapy)
Prior Antihyperglycemic (AHA) Medication (Monotherapy or Dual Therapy)(Participants)Ertugliflozin 5 mgErtugliflozin 15 mgGlimepirideTotal
Prior Antihyperglycemic Medication4484394371324
No Prior Use & Not on Antihyperglycemic Medication0101
Data not available0101
Estimated Glomerular Filtration Rate (eGFR)
Estimated Glomerular Filtration Rate (eGFR)(milliliters/minute/1.73 meters^2)Ertugliflozin 5 mgErtugliflozin 15 mgGlimepirideTotal
Mean88.3 ± 18.786.7 ± 18.386.6 ± 18.587.2 ± 18.5
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Hollander P, Hill J, Johnson J, Wei Jiang Z, Golm G, Huyck S, Terra SG, Mancuso JP, Engel SS, Lauring B, Liu J. Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. Curr Med Res Opin. 2019 Aug;35(8):1335-1343. doi: 10.1080/03007995.2019.1583450. Epub 2019 Mar 25. PubMed 30760125 ↗
  • Gallo S, Calle RA, Terra SG, Pong A, Tarasenko L, Raji A. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. Diabetes Ther. 2020 Aug;11(8):1849-1860. doi: 10.1007/s13300-020-00867-1. Epub 2020 Jul 9. PubMed 32648108 ↗
  • Patel S, Hickman A, Frederich R, Johnson S, Huyck S, Mancuso JP, Gantz I, Terra SG. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials. Diabetes Ther. 2020 Jun;11(6):1347-1367. doi: 10.1007/s13300-020-00803-3. Epub 2020 May 5. PubMed 32372382 ↗
  • Liu J, Tarasenko L, Pong A, Huyck S, Wu L, Patel S, Hickman A, Mancuso JP, Gantz I, Terra SG. Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Aug;36(8):1277-1284. doi: 10.1080/03007995.2020.1760228. Epub 2020 May 13. PubMed 32324082 ↗
  • Liu J, Tarasenko L, Pong A, Huyck S, Patel S, Hickman A, Mancuso JP, Ellison MC, Gantz I, Terra SG. Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Jul;36(7):1097-1106. doi: 10.1080/03007995.2020.1760227. Epub 2020 May 13. PubMed 32324065 ↗
  • Cherney DZI, Heerspink HJL, Frederich R, Maldonado M, Liu J, Pong A, Xu ZJ, Patel S, Hickman A, Mancuso JP, Gantz I, Terra SG. Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials. Diabetologia. 2020 Jun;63(6):1128-1140. doi: 10.1007/s00125-020-05133-4. Epub 2020 Mar 31. PubMed 32236732 ↗
  • Liu J, Patel S, Cater NB, Wu L, Huyck S, Terra SG, Hickman A, Darekar A, Pong A, Gantz I. Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2020 Apr;22(4):574-582. doi: 10.1111/dom.13931. Epub 2020 Jan 3. PubMed 31797522 ↗
  • Hollander P, Liu J, Hill J, Johnson J, Jiang ZW, Golm G, Huyck S, Terra SG, Mancuso JP, Engel SS, Lauring B. Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study. Diabetes Ther. 2018 Feb;9(1):193-207. doi: 10.1007/s13300-017-0354-4. Epub 2017 Dec 27. PubMed 29282633 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Apr 2017, 40 months.

Results were first posted in May 2018, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 40 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2013
First posted
Dec 3, 2013
StartActual
Dec 16, 2013
Primary completionActual
Apr 18, 2017
CompletionActual
Apr 18, 2017
Results first posted
May 11, 2018
Last update
Apr 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01999218
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Dec 3, 2013
Start date
Dec 16, 2013
Primary completion
Apr 18, 2017
Completion
Apr 18, 2017
Results posted
May 11, 2018
Last update
Apr 2, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ertugliflozin

Start the discussion